ArticleNational science review2022
Bioavailability of nanomaterials: bridging the gap between nanostructures and their bioactivity.
Article in National science review, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- In vivo dynamic hotspot-enhanced Raman spectroscopy via reconfigurable swarming nanoprobes.Nature communications · 2026Article
- Contrast-sparing CT using renal-clearable gold nanoclusters for early spatial mapping of renal dysfunction.Science advances · 2026Article
- Multimodal techniques based on synchrotron radiation X-rays for revealing interactions of metallic nanoparticles with biological matrices.Fundamental research · 2026Review
- Extreme Tolerance of Nanoparticle-Protein Corona to Ultra-High Abundance Proteins Enhances the Depth of Serum Proteomics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Intrinsic gallium-68 labeling of nanoclays forJournal of pharmaceutical analysis · 2025Article
- Nanotechnology in food systems: opportunities and risks for human health.Biotechnologia · 2025Review
- Review
- Limitations and Modifications of Skin Sensitization NAMs for Testing Inorganic Nanomaterials.Toxics · 2024Article
- In situ label-free X-ray imaging for visualizing the localization of nanomedicines and subcellular architecture in intact single cells.Nature protocols · 2024Review
- Advancement of regulating cellular signaling pathways in NSCLC target therapy via nanodrug.Frontiers in chemistry · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Instead of the nanostructure and biological activity, this perspective highlights the metabolic processes from biotransformation to bioavailability, to bridge the gap between the cradle (structure design) and endpoint (efficacy and/or safety) of nanomedicines.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.